Protocol Title: Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer (S1417CD)

Target Population:
- Stage IVA Colon Cancer
- Stage IVB Colon Cancer
- Stage IVA Rectal Cancer
- Stage IVB Rectal Cancer

Summary: To estimate the incidence of treatment-related major financial hardship over 12 Months, among patients with newly diagnosed Metastatic Colorectal Cancer (mCRC) treated at components and subcomponents of the National Cancer Institute (NCI) Community Oncology Research Program (NCORP).

Key Inclusion Criteria:
- Patients must have newly diagnosed metastatic Colon or Rectal Cancer (mCRC) (de novo metastatic diagnosis or metastatic recurrence) after prior treatment for Stage I-III disease and be within 120 Days after diagnosis at time of registration.
- Systemic chemotherapy and/or systemic biologic therapy must be planned to be administered within 30 Days after registration or must have been initiated within 60 Days prior to registration.
  - Patients who are planning palliative or hospice care only (no chemotherapy or biologic therapy) are not eligible.
- Patients must plan to receive treatment at the registering site.
  - Registering site must be an NCORP site.
- Patients must provide their full name, primary address in the United States, birth date, and social security number at registration for the purposes of accessing credit report data.
- Patients must sign and give written informed consent in accordance with institutional and federal guidelines.
- As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 Days) date of institutional review board approval for this study has been entered in the system.

Contacts:
Principal Investigator: Robert Ramirez, DO
Research Nurses (RN): Dana Feist (dana.feist@ochsner.org, ext. 26330)

For additional information: https://clinicaltrials.gov/ct2/show/NCT02728804